newsfilter
← Latest News
Business Wire·

Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb - Acceleron Pharma Inc. (NASDAQ:XLRN), a bioph